Antithrombotic Therapy in Atrial Fibrillation : – Evaluation and Positioning of New Oral Anticoagulant Agents –
スポンサーリンク
概要
- 論文の詳細を見る
Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for stroke. For more than 60 years, warfarin has been the only approved anticoagulant for prevention of stroke in patients with AF. Although highly effective, it has many limitations that make its use difficult. Therefore, several novel anticoagulants are under development to overcome the limitations of warfarin, and some of these have entered phase III clinical trials. Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery. It has also been approved in the United States and Japan for the prevention of stroke and systemic embolism in patients with nonvalvular AF. In this review, the mechanism of action and pharmacological properties of new anticoagulants are described in detail, and the correct use of dabigatran in clinical practice is discussed. (Circ J 2011; 75: 1539-1547)
論文 | ランダム
- 紫外線吸收すぺくとるノ研究(本學第116回學術集談會)
- 見方・考え方を育てる地理の授業(6)消費の見方・考え方
- シリ-ズ旅の記憶-26-山村を訪ねる--伊那谷周辺
- 住みやすい場をどう創るか(地理教育の提言 「世の中」と地理)
- シニアの地理教育-27-地域をみる眼を養う